skip to content

Cambridge Biosciences DTP PhD Programme

 
Milena Malcharek, BBSRC DTP student - Cohort 2023

A BBSRC DTP student, Milena Malcharek, has achieved a significant milestone by publishing her first paper in the prestigious Journal of Molecular Endocrinology. Her review investigates the critical role of receptor activity-modifying proteins (RAMPs) in the pathophysiology of obesity and diabetes mellitus.

What Are RAMPs?

RAMPs are specialized molecules that influence the activity of class B1 G protein-coupled receptors (GPCRs), which regulate essential processes like food intake, energy metabolism, and glucose balance. Dysregulation of these pathways can lead to obesity and diabetes, making RAMPs a vital focus for research.

Why Are RAMPs Important?

While much is known about class B1 receptors and their peptide activators (agonists) in obesity and diabetes, the role of RAMPs is less understood. The review by Malcharek et al. highlights:

  • RAMP Knockout Studies: Research shows that removing RAMPs disrupts metabolic regulation, but the details are complex and sometimes conflicting.
  • Disease-Driven Changes: Obesity and diabetes can alter the expression of RAMPs, receptors, and their agonists, with varying effects on disease progression.
  • Focus on the Calcitonin Family: The calcitonin receptor family has well-established RAMP interactions, providing a foundation for understanding their roles in metabolism.
  • Emerging Connections: New findings highlight interactions between RAMPs and other receptors implicated in obesity and diabetes, opening new avenues for exploration.

Future Implications

Despite the progress, more research is needed to untangle the complex roles of RAMPs and identify how they can be targeted for therapies. This field holds promise for breakthroughs in managing global health challenges like obesity and diabetes.
 

About Milena Malcharek

Milena is a second year PhD student in the Department of Pharmacology and part of the Cell Signalling Group led by Professor Graham Ladds. Her iCASE collaboration with AstraZeneca focuses on amylin receptor (AMYR) signalling, using cutting-edge bioassays to study how AMYR agonists regulate satiation. The goal is to contribute to the development of innovative anti-obesity treatments by deepening our understanding of these pathways.

Read the full article in the Journal of Molecular Endocrinology.

Latest news

Celebrating Student Research at the Cambridge Biosciences DTP Symposium 2025

25 July 2025

On Tuesday 22 July, the Cambridge Biosciences Doctoral Training Partnership (DTP) held its Annual Student Symposium at Robinson College. The event celebrated the great research students are doing and helped bring people in the Cambridge Biosciences community closer together.

PIPS Symposium 2025: Connecting Students with Future Opportunities

1 April 2025

Our annual PIPS Symposium took place on Friday, 28 March, at the Babraham Campus, bringing together students and host organisations for a half-day of networking, insights, and career development opportunities. The event is designed to support current students who have yet to complete their PIPS by connecting them with potential host organisations across various sectors.

Cambridge Researchers Identify Genes Linked to Obesity in Both Dogs and Humans

17 March 2025

Dr. Natalie Wallis and Dr. Alyce McClellan, both alumnae of the Cambridge Biosciences DTP programme (2019 cohort), are joint first authors on a groundbreaking study published in Science.